Synth-Med is revolutionizing drug delivery by leveraging the unique properties of red blood cells (RBCs), the body’s most abundant and naturally biocompatible carriers. RBCs have low immunogenicity and an exceptionally long circulation half-life, making them ideal for therapeutic delivery. While others have attempted similar approaches, Synth-Med is the first to overcome key technical barriers without relying on gene therapy. Our proprietary platform enables targeted delivery of a wide range of drug types. Our lead asset delivers a memory-enhancing molecule to the brain, addressing a critical unmet need in Alzheimer’s disease and opening new frontiers in disease treatment.